Celgene to collaborate with tiny Jounce on cancer immunotherapy

Celgene to collaborate with tiny Jounce on cancer immunotherapy


Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts-based company comes just at little more than three years after it was launched with funding from life sciences investor Third Rock Ventures.



from Biotech News